Evoke Wealth LLC Takes Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Evoke Wealth LLC bought a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 15,373 shares of the specialty pharmaceutical company’s stock, valued at approximately $181,000.

A number of other institutional investors have also made changes to their positions in KALV. nVerses Capital LLC bought a new position in KalVista Pharmaceuticals during the second quarter worth $25,000. EntryPoint Capital LLC bought a new stake in shares of KalVista Pharmaceuticals during the 1st quarter worth about $92,000. China Universal Asset Management Co. Ltd. grew its stake in KalVista Pharmaceuticals by 101.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 8,024 shares of the specialty pharmaceutical company’s stock valued at $95,000 after buying an additional 4,043 shares during the last quarter. Entropy Technologies LP acquired a new position in KalVista Pharmaceuticals in the 1st quarter valued at about $121,000. Finally, PEAK6 Investments LLC bought a new position in KalVista Pharmaceuticals in the 1st quarter valued at about $178,000.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th.

Insider Buying and Selling

In other news, CEO Benjamin L. Palleiko sold 14,215 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $12.01, for a total value of $170,722.15. Following the completion of the transaction, the chief executive officer now directly owns 242,527 shares in the company, valued at approximately $2,912,749.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Benjamin L. Palleiko sold 14,215 shares of the business’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $170,722.15. Following the completion of the transaction, the chief executive officer now owns 242,527 shares of the company’s stock, valued at approximately $2,912,749.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Benjamin L. Palleiko sold 7,352 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $12.19, for a total value of $89,620.88. Following the completion of the sale, the chief executive officer now directly owns 250,800 shares in the company, valued at $3,057,252. The disclosure for this sale can be found here. Insiders sold 30,804 shares of company stock valued at $372,112 over the last quarter. 12.30% of the stock is owned by company insiders.

KalVista Pharmaceuticals Stock Down 4.6 %

Shares of NASDAQ:KALV opened at $10.49 on Friday. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.21 and a 12-month high of $16.88. The company’s 50 day moving average price is $12.92 and its two-hundred day moving average price is $12.22. The firm has a market cap of $442.55 million, a PE ratio of -3.09 and a beta of 0.89.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.04. On average, research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.35 EPS for the current year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.